Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Operating Expenses (2016 - 2025)

Lineage Cell Therapeutics' Operating Expenses history spans 16 years, with the latest figure at $13.2 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 64.9% year-over-year to $13.2 million; the TTM value through Dec 2025 reached $51.2 million, up 65.2%, while the annual FY2025 figure was $51.2 million, 65.2% up from the prior year.
  • Operating Expenses reached $13.2 million in Q4 2025 per LCTX's latest filing, up from $7.5 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $29.2 million in Q4 2021 to a low of $7.3 million in Q2 2024.
  • Average Operating Expenses over 5 years is $10.2 million, with a median of $8.1 million recorded in 2021.
  • Peak YoY movement for Operating Expenses: skyrocketed 376.92% in 2021, then plummeted 71.06% in 2022.
  • A 5-year view of Operating Expenses shows it stood at $29.2 million in 2021, then tumbled by 71.06% to $8.5 million in 2022, then fell by 3.05% to $8.2 million in 2023, then fell by 2.64% to $8.0 million in 2024, then surged by 64.9% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Operating Expenses are $13.2 million (Q4 2025), $7.5 million (Q3 2025), and $22.5 million (Q2 2025).